FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:77-79 January 5, 2006 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Armstrong, D. K. PubMed Citation

Patients with advanced epithelial ovarian cancer typically receive intravenous taxane and platinum-based chemotherapy in an attempt to eradicate residual disease after surgical debulking. This treatment yields overall median survivals of approximately 37 months in patients with suboptimally debulked disease (residual tumor, >1.0 cm in diameter) and 49 months in those with optimally debulked disease (residual tumor, 1.0 cm in diameter).¹ Despite high response rates, in most patients relapse occurs, and efforts to improve treatment by escalating the doses of intravenous chemotherapy have been largely unsuccessful.² In contrast to intravenous drug administration, the intraperitoneal route is capable of achieving high local . . . [Full Text of this Article]

Source Information

From the Beth Israel Deaconess Medical Center and Harvard Medical School — both in Boston.

This article has been cited by other articles:

• Huang, Y.-H., Zugates, G. T., Peng, W., Holtz, D., Dunton, C., Green, J. J., Hossain, N., Chernick, M. R., Padera, R. F. Jr., Langer, R., Anderson, D. G., Sawicki, J. A. (2009). Nanoparticle-Delivered Suicide Gene Therapy Effectively Reduces Ovarian Tumor Burden in Mice. Cancer Res. 69: 6184-6191 [Abstract] [Full Text]  
• Huang, Y.-H., Bao, Y., Peng, W., Goldberg, M., Love, K., Bumcrot, D. A., Cole, G., Langer, R., Anderson, D. G., Sawicki, J. A. (2009). Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 106: 3426-3430 [Abstract] [Full Text]  
• Jandial, D. D., Farshchi-Heydari, S., Larson, C. A., Elliott, G. I., Wrasidlo, W. J., Howell, S. B. (2009). Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1. Clin. Cancer Res. 15: 553-560 [Abstract] [Full Text]  
• Cannistra, S. A., McGuire, W. P. (2007). Progress in the Management of Gynecologic Cancer. JCO 25: 2865-2866 [Full Text]  
• Yan, T., Welch, L, Black, D, Sugarbaker, P. (2007). A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18: 827-834 [Abstract] [Full Text]  
• Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., Cella, D. (2007). Health-Related Quality of Life During and After Intraperitoneal Versus Intravenous Chemotherapy for Optimally Debulked Ovarian Cancer: A Gynecologic Oncology Group Study. JCO 25: 437-443 [Abstract] [Full Text]  
• Gore, M., du Bois, A., Vergote, I. (2006). Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental. JCO 24: 4528-4530 [Full Text]  
• Armstrong, D. K., Brady, M. F. (2006). Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime Time. JCO 24: 4531-4533 [Full Text]  
• Yan, T. D., Black, D., Savady, R., Sugarbaker, P. H. (2006). Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma. JCO 24: 4011-4019 [Abstract] [Full Text]  
• (2006). Intraperitoneal Chemotherapy for Ovarian Cancer. JWatch Women's Health 2006: 2-2 [Full Text]  
• (2006). Intraperitoneal Chemotherapy for Ovarian Cancer Prolongs Survival. JWatch General 2006: 1-1 [Full Text]